Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization process
May 03, 2024 11:30 ET
|
Mithra Pharmaceuticals
Liege, Belgium, 3 May 2024 – 17:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces that, after diligent evaluation of several binding offers, Mithra...
Sterke resultaten in het 1ste kwartaal van 2024 met voortzetting van omzetgroei en margeverbetering
May 03, 2024 01:00 ET
|
Ontex
Omzet groeide 4% op vergelijkbare basis, dankzij volumes in Noord-Amerika;Aangepaste EBITDA-marge steeg met 24,4 procentpunt tot 11,5%, aangedreven door het kostentransformatieprogramma;Hefboomratio...
Strong Q1 2024 results with continued revenue growth and margin improvement
May 03, 2024 01:00 ET
|
Ontex
Revenue grew 4% like for like, driven by volumes in North America;Adjusted EBITDA margin rose 2.4pp to 11.5%, fueled by cost transformation program;Leverage ratio reduced from 3.3x to 2.8x over...
Conversion of Subscription Rights [Change in denominator]
May 03, 2024 01:00 ET
|
Unifiedpost
Press Release - Regulated Information La Hulpe, Belgium, 3 May 2024, 7.00 a.m. CET — [REGULATED INFORMATION] Unifiedpost Group (Euronext Brussels: UPG) (“Unifiedpost”), a leading provider of...
Avis de convocation à l’assemblée générale 2024 des actionnaires ONWARD® et propositions de résolutions
May 02, 2024 21:31 ET
|
ONWARD Medical NV
EINDHOVEN, Pays-Bas, 03 mai 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale à l’origine de thérapies innovantes ciblées sur la restauration du...
Galapagos rapporteert financiële resultaten voor het eerste kwartaal 2024
May 02, 2024 16:01 ET
|
Galapagos NV
Vooruitgang met potentiële best-in-class R&D pijplijn van celtherapie en kleine moleculen, met vier klinische assets en >15 onderzoeksprogramma's in oncologie en immunologie Overeenkomsten...
Galapagos reports first quarter 2024 financial results
May 02, 2024 16:01 ET
|
Galapagos NV
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with...
Orange Belgium finalise son augmentation de capital par apport en nature - Nethys échange sa participation dans VOO Holding contre des actions nouvellement émises d'Orange Belgium
May 02, 2024 13:00 ET
|
Orange Belgium
Communiqué de presseBruxelles, le 2 mai 2024Information réglementée – informations confidentielles Orange Belgium finalise son augmentation de capital par apport en nature - Nethys échange sa...
Orange Belgium voltooit zijn kapitaalverhoging door inbreng in natura – Nethys ruilt zijn belang in VOO Holding in voor nieuw uitgegeven aandelen van Orange Belgium
May 02, 2024 13:00 ET
|
Orange Belgium
PersberichtBrussel, 2 mei 2024Gereglementeerde informatie – Voorwetenschap Orange Belgium voltooit zijn kapitaalverhoging door inbreng in natura – Nethys ruilt zijn belang in VOO Holding in...
Orange Belgium completes its capital increase by contribution in kind – Nethys exchanges its stake in VOO Holding for newly issued shares of Orange Belgium
May 02, 2024 13:00 ET
|
Orange Belgium
Press releaseBrussels, 2 May 2024Regulated information – Inside information Orange Belgium completes its capital increase by contribution in kind – Nethys exchanges its stake in VOO Holding for newly...